ArticlePloS one2026
Does C-reactive protein exhibit high prognostic information value in acute pulmonary embolism? A novel structural pathway for disease progression beyond classical statistical associations.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Malignancy as a Predictor and Potential Modifier of Laboratory Biomarker Prognostic Value in Acute Pulmonary Embolism.Diagnostics (Basel, Switzerland) · 2026Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute pulmonary embolism (APE) is a life-threatening condition requiring precise risk stratification. Although numerous prognostic factors have been proposed, redundancy and limited predictive utility often obscure clinical interpretation. To analyze a predefined set of clinical and laboratory variables in patients with APE using both classical statistical models and a novel taxonomic structural analysis, aiming to identify factors associated with early mortality beyond conventional outcome-based associations. We retrospectively analyzed 366 patients diagnosed with APE between 2009 and 2018, of whom 76 died within one year of the acute event. A total of 20 clinical and laboratory variables-including both established prognostic markers and features with no presumed direct impact on mortality-were assessed using Cox and logistic regression models with the concordance index (C-index) and Akaike's Information Criterion (AIC). A structural analysis based on Marczewski-Steinhaus (M-S) taxonomic distances was applied to all 1,140 unique triads of risk factors to identify clusters of high patient variability. Segmented regression was then used to determine the transition between homogeneous and heterogeneous predictor spaces. Classical regression identified age as the strongest mortality predictor in APE. In contrast, the taxonomic outcome-agnostic approach revealed CRP as the most prominent structural signal, followed by other key inflammatory markers such as D-dimer, high-sensitivity troponin T (hsTnT), and activated partial thromboplastin time (aPTT). Age, along with certain hematological parameters (e.g., hemoglobin) and major electrolytes (Na ⁺ , K ⁺ , Cl⁻), appeared taxonomically insensitive to acute disease-related changes, reflecting more stable background characteristics. Several other variables, including renal biomarkers (urea, creatinine, and GFR), showed no significant role in APE, with their levels varying randomly between patients. Within this framework, CRP exhibits the highest structural variability among the analyzed factors, suggesting prognostic relevance beyond classical outcome-based associations (such as age). The proposed taxonomic approach complements traditional methods by reducing redundancy, enhancing interpretability, and improving the identification of truly relevant prognostic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.